RhumbLine Advisers
CADL icon

RhumbLine Advisers’s Candel Therapeutics CADL Stock Holding History

RhumbLine Advisers’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$804K Buy
78,045
+26,646
+52% +$201K ﹤0.01% 2458
2026
Q1 		$252K Buy
51,399
+394
+0.8% +$2.14K ﹤0.01% 3007
2025
Q4 		$288K Sell
51,005
-2,635
-5% -$14.2K ﹤0.01% 2996
2025
Q3 		$274K Sell
53,640
-858
-2% -$4.96K ﹤0.01% 3058
2025
Q2 		$276K Buy
54,498
+21,196
+64% +$109K ﹤0.01% 3045
2025
Q1 		$188K Buy
33,302
+7,030
+27% +$57.4K ﹤0.01% 3130
2024
Q4 		$228K Buy
26,272
+3,817
+17% +$22.6K ﹤0.01% 3123
2024
Q3 		$156K Sell
22,455
-530
-2% -$3.29K ﹤0.01% 3345
2024
Q2 		$143K Buy
+22,985
New +$173K ﹤0.01% 3395

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RhumbLine Advisers's CADL Position: Q2 2026 in Review

RhumbLine Advisers increased its Candel Therapeutics (CADL) stake by 52% in Q2 2026, buying an estimated $201K and bringing the position to 78,045 shares worth $804K. The position accounts for ﹤0.01% of the portfolio, ranked #2458.

RhumbLine Advisers first reported a position in CADL in Q2 2024 and has held it in 9 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • RhumbLine Advisers held 78,045 shares of Candel Therapeutics worth $804K as of Q2 2026.
  • RhumbLine Advisers bought 26,646 Candel Therapeutics shares in Q2 2026, an estimated $201K.
  • Candel Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2458 holding.
  • RhumbLine Advisers first reported a position in Candel Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.